Immune-related saliva micro-RNA’s to predict clinical response to a combination of cetuximab and low-dose chemotherapy in head and neck cancer (HNSCC) patients (pts) with poor performance status (PS).
New York, May 03, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Voice Prosthesis Device Market Research Report by Valve, by Device, by End User - Global Forecast to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results